Clinical-stage biotech Alzheon has completed a $100 million Series E financing round to advance the development and commercialization of its oral drug for Alzheimer’s disease. The drug, called ALZ-801 (valiltramiprosate), is designed to inhibit the formation of soluble toxic beta amyloid oligomers, which are implicated in the cognitive decline observed in Alzheimer’s patients. The small molecule acts upstream of other late-stage amyloid-targeting treatments, offering a potentially more effective intervention by addressing the early formation of neurotoxic aggregates.
The new funding will be used to complete the current APOLLOE4 Phase 3 study to evaluate the efficacy and safety of ALZ-801 in patients with early Alzheimer’s disease. It will also support Alzheon’s plans to submit a New Drug Application (NDA) in 2024 based on the study’s outcomes, as well as preparing the manufacturing processes and commercial launch of ALZ-801, which is potentially the first oral disease-modifying therapy for Alzheimer’s.
“This latest fundraising ensures that we will have sufficient capital to complete our pivotal Phase 3 program and prepare commercialization of oral ALZ-801/valiltramiprosate with runway well into 2026,” said Ken Mace, CFO of Alzheon. “ALZ-801 has the potential to disrupt the Alzheimer’s treatment paradigm by slowing the progression of this relentless and debilitating disease, and the results from our pivotal APOLLOE4 Phase 3 trial will set the stage for the potential NDA filing this year, followed by the U.S. commercial launch in 2025.”
The pivotal APOLLOE4 Phase 3 study particularly targets patients with two copies of the APOE4/4 gene, a high-risk group that constitutes approximately 15% of Alzheimer’s patients, including actor Chris Hemsworth. The study, which has screened over 6,000 patients and enrolled 325 subjects, will conclude in the third quarter of 2024. Positive results could pave the way for regulatory approval and subsequent commercialization.
“We are at the dawn of a new era in the treatment of Alzheimer’s disease, and our novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients,” said Dr Martin Tolar, CEO of Alzheon. “Our well-differentiated drug candidate with a favorable safety profile, showing no increased risk of vasogenic brain edema in more than 3,000 AD patients, is positioned to potentially become the first oral disease modifying therapy for the treatment of Alzheimer’s disease.”
In addition to the Phase 3 study, ALZ-801 has been evaluated in a two-year Phase 2 biomarker trial involving 84 patients, including 31 APOE4/4 homozygotes. This trial, completed in late 2023, is currently in a fourth-year extension phase. The study’s primary goal is to assess the effects of ALZ-801 on biomarkers of Alzheimer’s pathology, alongside its clinical efficacy, safety, tolerability, and pharmacokinetic profile over 208 weeks of treatment.
Alzheon envisions extending the use of ALZ-801 beyond APOE4/4 homozygotes to include patients with one copy of the APOE4 gene and even noncarriers. The company says it is also focusing on a future precision medicine approach, leveraging individual genetic and biomarker information to tailor therapies that offer the greatest benefit to specific patient subsets.
The funding round, which was led by Alerce Medical Technology Partners, follows a $50 million Series D round completed in 2022.
“At Alerce, we focus on investing in companies in the late stages of development that are developing lifesaving drugs or devices with the potential to benefit millions of patient lives,” said Muneer Satter, Managing Partner of Alerce. “Alzheon’s ALZ-801 provides an innovative precision-medicine solution in an emerging Alzheimer’s pipeline with a path to potential approval in 2025.”
News
The Global Nanomedicine Market: Key Players and Emerging Technologies in Healthcare
This article provides an overview of the global nanomedicine market, highlighting key players, emerging technologies, and the challenges and opportunities that influence its growth and commercialization in the healthcare sector. Nanomedicines are nanotechnology-based drug products [...]
Scientists Have Discovered Toxic “Forever Chemicals” in Bottled Water
Scientists have found toxic PFAS in drinking water samples from around the world, with higher levels in tap water from China compared to the UK. Boiling water or using a filtration jug can reduce [...]
Urban Microbes Are Eating Disinfectants – Are We Fueling a New Health Threat?
New research reveals that microbes in urban environments are evolving to withstand the very cleaning agents designed to eliminate them. The study also uncovers new strains in Hong Kong, previously only found in the [...]
Startling Study Shows High-Potency Cannabis Alters DNA
The study shows that frequent use of high-potency cannabis alters DNA, affecting genes related to energy and immune function. These changes differ between those with and without psychosis, suggesting cannabis use could influence mental health through biological [...]
New nanotherapy targets artery inflammation in cardiovascular disease
Inflammation of the arteries is a primary precursor and driver of cardiovascular disease—the No. 1 killer of people in the United States. This inflammation is associated with the buildup of dangerous plaque inside the [...]
Revolutionary Nanoparticle Therapy for Prostate Cancer
A groundbreaking research effort involving teams from the University of Virginia, Mount Sinai, the University of Michigan, the University of Texas, and others has displayed the clinical efficacy of an innovative therapy that utilizes nanoparticles and [...]
Antibody engineering drives innovation in drug development
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound [...]
Breakthrough Study Reveals How Bladder Cancer Starts and Spreads
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal circular DNA in tumor cells drives resistance to therapy. These discoveries open new therapeutic avenues. A groundbreaking study led by [...]
AI and Quantum Mechanics Accelerate Drug Discovery
A recent article published in the Journal of Chemical Information and Modeling researchers at Southern Methodist University (SMU) have developed SmartCADD, an open-source virtual tool designed to speed [...]
Targeting ‘undruggable’ diseases: Researchers reveal new levels of detail in targeted protein degradation
Researchers at the University of Dundee have revealed in the greatest detail yet the workings of molecules called protein degraders which can be deployed to combat what have previously been regarded as "undruggable" diseases, [...]
Revolutionizing Virology: AI Discovers Over 160,000 New RNA Viruses
Largest discovery of new virus species sheds light on the hidden virosphere. Artificial intelligence (AI) has been used to reveal details of a diverse and fundamental branch of life living right under our feet and in every [...]
Cardiac Crisis: COVID-19 Doubles Risk of Heart Attacks, Strokes, and Death
Research indicates that COVID-19 survivors face doubled risks of severe cardiac events for years after recovery, especially if hospitalized. People with A, B, or AB blood types are particularly vulnerable, highlighting the need for personalized approaches [...]
AI steps into science limelight with Nobel wins
For long periods of its history, artificial intelligence has lurked in the hinterland of science, often unloved and unfunded—but two Nobel prizes in one week suggest its time in the sunshine has finally arrived. [...]
MIT Scientists Shed New Light on the Critical Brain Connections That Define Consciousness
A new study provides further evidence that consciousness depends on communication between the brain’s sensory and cognitive regions in the cortex. Our brains are constantly making predictions about our surroundings, enabling us to focus [...]
Common Chemicals Found in Shampoo and Plastic Could Be Quietly Disrupting Your Heart’s Rhythm
UC study of Fernald data links environmental phenols to heart toxicities Environmental phenols are present in numerous everyday consumer products, serving as preservatives in packaged foods, parabens in shampoos, and bisphenol A (BPA) in [...]
Revolutionary Brain Tech Offers New Hope for Stroke and Injury Recovery
University of Pittsburgh researchers report that deep brain stimulation (DBS) can effectively enhance motor functions in individuals with arm and hand paralysis due to brain injuries, with promising results from early human and monkey [...]
